An Introduction to Immunotherapy
Cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Monoclonal antibodies and immune checkpoint inhibitors are now an established part of the treatment paradigm for many types of cancer, but challenges remain around its efficacy, targeting and toxicity.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma
touchREVIEWS in Oncology & Haematology. 2023;9(1):Online ahead of journal publication
Cancers of the anal canal are relatively uncommon, and account for less than 1% of all new cancer diagnoses in the UK.1 However, the incidence of these cancers has increased over the past decade, primarily in females, in which they have more than doubled.1 Squamous cell anal carcinoma (SCAC) is the most common type of anal cancer, with adenocarcinomas, neuroendocrine carcinomas […]
Emerging data with immunotherapy in esophageal squamous cell carcinoma and potential impact for clinical practice
Join Dr Elizabeth Smyth as she highlights the latest clinical data on the use of immunotherapy in the management of esophageal squamous cell carcinoma (ESCC).
- Describe the efficacy data for emerging treatments, including first- and second-line immunotherapy, for ESCC
- Recall the safety data for emerging treatments for ESCC
- Discuss how the latest data for emerging treatments for ESCC could impact clinical practice
Immunogenicity of immune checkpoint inhibitors: What are the implications for clinical practice?
Watch three experts discuss the clinical relevance of the immunogenicity of immune checkpoint inhibitors for the treatment of cancer, informed by experience in inflammatory diseases.
- Describe the experience of immunogenicity from the use of biologic therapies in chronic inflammatory diseases, and how this might inform the use of immune checkpoint inhibitors in oncology
- Review the current data for the immunogenicity of immune checkpoint inhibitors and how anti-drug antibodies impact drug efficacy and safety
- Discuss the potential clinical implications of ADAs in oncology and possible strategies for management
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
Watch three experts discuss the pathophysiology of cold agglutinin disease (CAD) and the steps needed for an accurate diagnosis. The panel goes on to discuss how emerging treatment options are changing the management of patients with primary CAD and the importance of tailoring treatment to improve outcomes. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.
- Describe the immunopathogenesis of cold agglutinin disease (CAD) and implications for effective patient management
- Appraise current and emerging treatment options for patients with CAD using the latest data
- Evaluate strategies to individualize the treatment and management of patients with CAD
Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022
Watch this two-part activity exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer. Filmed following the ESMO 2022 Congress. Part 1: Watch urological cancer expert Prof. Axel Merseburger review key data from the ESMO Congress 2022 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
- Recall the latest efficacy data for new and emerging targeted treatments for patients with bladder cancer
- Describe the safety profile of new and emerging targeted treatments for patients with bladder cancer
- Discuss how the latest data on targeted treatments may affect the current and future management of patients with bladder cancer
Exploring the latest advances in first-line treatment of ES-SCLC: Translating the data to clinical practice
Watch leading lung cancer experts share their insights on the latest advancements in first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
- Recall the latest data on the efficacy of ICI-combination approaches for ES-SCLC in the first-line setting
- Describe the latest safety data for ICI-combination approaches for patients with ES-SCLC
- Discuss ongoing ICI clinical trial data and preclinical trials in ES-SCLC
Improving outcomes for patients with advanced RCC: What is the role of emerging combination therapies in the first-line setting?
Watch genitourinary oncology experts discuss how emerging combination therapies in the first-line treatment of advanced RCC can improve patient outcomes.
- Evaluate the rationale for the use of combination therapy in patients with advanced RCC
- Discuss the latest efficacy and safety data for established and emerging combination therapies in first-line advanced RCC
- Apply best practice in the management of adverse events associated with combination therapies for first-line advanced RCC
Optimizing the patient journey in CSCC through multidisciplinary collaboration
In this activity, leading experts discuss optimal approaches for the management of patients with CSCC and consider how effective multidisciplinary collaboration can contribute to improved outcomes.
- Define multidisciplinary best practices for diagnostic workup of cutaneous squamous cell carcinoma (CSCC) and identification of risk factors influencing prognosis
- Outline interdisciplinary eligibility criteria for surgery and radiotherapy in patients with CSCC
- Determine the optimal use of systemic therapies in patients with unresectable locally advanced or metastatic CSCC and the role of the multidisciplinary tumour board in sharing clinical decisions in cancer care
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!